Elena Nironi

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression

P. Lollini, M. Arigoni, R. Calogero, 2021, Oncogenesis.

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC

M. Ferracin, P. Lollini, M. Fiorentino, 2022, Translational lung cancer research.